Sue D. Pedersen

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark et al. · New England Journal of Medicine · 2019 · 1.9K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Obesity in adults: a clinical practice guideline

Sean Wharton, David C.W. Lau, Michael Vallis et al. · Canadian Medical Association Journal · 2020 · 1.4K citations · Full text

Agriculture, Nutrition, Clinical Epidemiology +16

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Melanie J. Davies, Louise Færch, Ole Kleist Jeppesen et al. · The Lancet · 2021 · 1.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial

Patrick M. O’Neil, Andreas L. Birkenfeld, Barbara McGowan et al. · The Lancet · 2018 · 804 citations

Pharmacy, Pharmacology, Pharmacotherapy +13